×
About 44,888 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  12,829 results

Acute Myeloid Leukaemia following Direct Acting Antiviral drugs in HCV-infected patient...
https://doi.org/10.1016/j.clinre.2022.102000
Clinics and Research in Hepatology and Gastroenterology; Carole S, Elena L et. al.

Aug 7th, 2022 - After several cases of peculiar hematological malignancies following introduction of new oral anti-hepatitis C virus (HCV) treatments in our recent practice, we aimed to systematically identify all cases of hematological malignancies (HM) in patie...

Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2...
https://doi.org/10.1016/j.leukres.2022.106921
Leukemia Research; Shah N, Delforge M et. al.

Aug 6th, 2022 - To understand the experience of patients with relapsed and refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in the pivotal, phase 2 KarMMa...

18F-Fluciclovine PET/CT: A Potential Imaging Biomarker for the Evaluation of Multiple M...
https://doi.org/10.1097/RLU.0000000000004271
Clinical Nuclear Medicine; Marcus C, Schuster DM et. al.

Aug 6th, 2022 - Incidental concomitant second primary malignancy may be detected on PET/CT imaging. We present an 18F-fluciclovine PET/CT of a patient undergoing evaluation of biochemically recurrent prostate cancer with incidental radiotracer uptake within lytic...

EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressi...
https://doi.org/10.1182/bloodadvances.2022007291
Blood Advances; Kikuchi J, Kodama N et. al.

Aug 6th, 2022 - Extramedullary disease (EMD) is known to be associated with chemoresistance and poor prognosis in multiple myeloma (MM); however, the mechanisms of its development are not fully understood. Elucidating the mechanism of EMD development and its ther...

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04445701

Aug 5th, 2022 - An open-label, multicenter, dose escalation study to evaluate the safety, tolerability and PK/pharmacodynamics of AO-176 in adults with relapsed/refractory multiple myeloma whose disease has progressed following at least 3 prior systemic lines of ...

see more →

Guidelines  36 results

Management of herpesvirus reactivations in patients with solid tumours and hematologic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810475
Annals of Hematology; Henze L, Buhl C et. al.

Jan 8th, 2022 - Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy ...

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive C...
https://doi.org/10.1016/j.clml.2021.07.028
Clinical Lymphoma, Myeloma & Leukemia; LeBlanc R, Bergstrom DJ et. al.

Aug 31st, 2021 - Multiple myeloma (MM) is a hematological cancer associated with significant symptomatic burden. Bone disease, renal insufficiency, cytopenias, infection, and peripheral neuropathy, among other disease manifestations and complications, impair patie...

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0057
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...

see more →

Drugs  168 results see all →

Clinicaltrials.gov  2,391 results

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04445701

Aug 5th, 2022 - An open-label, multicenter, dose escalation study to evaluate the safety, tolerability and PK/pharmacodynamics of AO-176 in adults with relapsed/refractory multiple myeloma whose disease has progressed following at least 3 prior systemic lines of ...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Aug 5th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT03338972

Aug 5th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the safety of adoptive therapy with ex vivo expanded autologous CD8+ plus CD4+ T cells transduced to express a human B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) for patients with rel...

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02465060

Aug 5th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
https://clinicaltrials.gov/ct2/show/NCT05297240

Aug 5th, 2022 - The proposal of this study is to retrospectively analyze the experience with belantamab mafodotin monotherapy in patients with RRMM included in the compassionate use or in the expanded access program in Spain between November 2019 and June 2021. S...

see more →

News  2,507 results

Quadruplet Tx in Myeloma May Reduce Need for Transplants
https://www.medscape.com/viewarticle/978095

Jul 27th, 2022 - New results with quadruple drug therapy in the frontline treatment of multiple myeloma (MM) are prompting experts to speculate that stem cell transplantation may soon be able to take a back seat in the treatment of newly diagnosed disease. “It is ...

Risky Business: Most Cancer Drugs Don't Reach the Market
https://www.medscape.com/viewarticle/977219

Jul 14th, 2022 - Only about 6% of cancer drugs tested in a phase 1 study in 2015 were ultimately approved by the US Food and Drug Administration (FDA) by 2021, a new analysis suggests. The researchers also found that about 8% of approved agents were subsequently t...

CMS Unveils Replacement for the Oncology Care Model
https://www.medscape.com/viewarticle/976709

Jul 7th, 2022 - The Centers for Medicare & Medicaid Services (CMS) has announced a new, voluntary alternative payment model, which will replace the Oncology Care Model (OCM) that ended on June 30. The OCM's successor, known as the Enhancing Oncology Model (EOM), ...

Triple-Class Refractory Multiple Myeloma: What Is the Approach? What Are the Challenges?
https://www.medscape.com/viewarticle/964339

Jul 5th, 2022 - This transcript has been edited for clarity. Joseph Mikhael, MD: Hello. My name is Dr Joseph Mikhael and welcome to Medscape InDiscussion: Multiple Myeloma. Today we're talking about triple-class refractory multiple myeloma. This is a particularly...

Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma
https://www.mdedge.com/fedprac/avaho/article/255829/multiple-myeloma/simultaneous-cases-carfilzomib-induced-thrombotic
Nathaniel J. Myall, MD, Samantha X. Wang, MD et. al.

Jun 28th, 2022 - As a class of drugs, proteasome inhibitors are known to rarely cause drug-induced thrombotic microangiopathy (DITMA). In particular, carfilzomib is a second-generation, irreversible proteasome inhibitor approved for the treatment of relapsed, refr.

see more →

Patient Education  24 results see all →